tradingkey.logo
tradingkey.logo
Search

Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors

ReutersMar 26, 2025 1:28 PM
facebooktwitterlinkedin

- Exelixis Inc EXEL.O:

  • EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NEUROENDOCRINE TUMORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI